Total Visits

Views
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study51

Total Visits Per Month

April 2021May 2021June 2021July 2021August 2021September 2021October 2021
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study4011001

File Downloads

Views
fonc-09-01320.xml21
fonc-09-01320.pdf12
additional-files.zip1

Top country views

Views
United States28
United Kingdom5
Germany3
Belgium2
China2
Ireland2
Brazil1
EU1
France1
Italy1

Top cities views

Views
Ashburn15
Oakland4
Dublin2
Edmond2
Fairfield2
Stekene2
Beijing1
Florence1
Fremont1
Matao1